Ceryx Medical announced that it closed a new funding round, bringing its total raised to $15 million to support its pacing technology.
The London-based company aims to revolutionise cardiac care through intelligent, adaptive pacing technology. Its lead product, a temporary cardiac pacing device, is currently undergoing clinical evaluation. The company noted “highly encouraging” early results in a news release. It says results show the potential to significantly enhance patient recovery following cardiac surgery.
Related: Positrigo closes $8.5M funding round
Ceryx says it expects its latest funding to help accelerate the development of its second product, a permanent device. The physiologically responsive pacemaker would provide long-term support for patients with chronic heart failure. It mimics the body’s natural modulation of the heart to deliver real-time, biomimetic pacing. This offers a more natural and effective treatment option, Ceryx says.
BGF, Parkwalk Advisors, Development Bank of Wales (DBW), and BBI, the company’s leading investors, supported the financing. Ceryx says they share its vision for intelligent bioelectronic systems enhancing heart failure care.
“This investment is a strong endorsement of our team, technology, and vision,” said Stuart Plant, CEO of Ceryx Medical. “The early clinical data from our temporary device has given us real momentum, and with this funding, we’re excited to advance our permanent pacing platform—an innovation that could redefine how heart failure is treated.”
